Kuros Biosciences Ag Stock Profit Margin
| CSBTF Stock | USD 27.34 0.26 0.94% |
Kuros Biosciences AG fundamentals help investors to digest information that contributes to Kuros Biosciences' financial success or failures. It also enables traders to predict the movement of Kuros Pink Sheet. The fundamental analysis module provides a way to measure Kuros Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kuros Biosciences pink sheet.
Kuros |
Kuros Biosciences AG Company Profit Margin Analysis
Kuros Biosciences' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Kuros Biosciences Profit Margin | (0.74) % |
Most of Kuros Biosciences' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kuros Biosciences AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Kuros Biosciences AG has a Profit Margin of -0.7352%. This is 93.44% lower than that of the Healthcare sector and 96.81% lower than that of the Biotechnology industry. The profit margin for all United States stocks is 42.11% lower than that of the firm.
Kuros Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kuros Biosciences' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kuros Biosciences could also be used in its relative valuation, which is a method of valuing Kuros Biosciences by comparing valuation metrics of similar companies.Kuros Biosciences is currently under evaluation in profit margin category among its peers.
Kuros Fundamentals
| Return On Equity | -0.14 | |||
| Return On Asset | -0.0667 | |||
| Profit Margin | (0.74) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 40.53 M | |||
| Shares Outstanding | 36.54 M | |||
| Shares Owned By Insiders | 35.33 % | |||
| Shares Owned By Institutions | 16.83 % | |||
| Price To Earning | 0.33 X | |||
| Price To Book | 0.79 X | |||
| Price To Sales | 4.63 X | |||
| Revenue | 13.81 M | |||
| Gross Profit | 10.07 M | |||
| EBITDA | (5.29 M) | |||
| Net Income | (7.54 M) | |||
| Cash And Equivalents | 28.62 M | |||
| Cash Per Share | 0.87 X | |||
| Total Debt | 2.21 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 2.91 X | |||
| Book Value Per Share | 2.23 X | |||
| Cash Flow From Operations | (5.45 M) | |||
| Earnings Per Share | (0.24) X | |||
| Number Of Employees | 64 | |||
| Beta | 0.77 | |||
| Market Capitalization | 70.16 M | |||
| Total Asset | 91.34 M | |||
| Retained Earnings | (37 M) | |||
| Working Capital | 16 M | |||
| Current Asset | 18 M | |||
| Current Liabilities | 2 M | |||
| Z Score | 18.6 | |||
| Net Asset | 91.34 M |
About Kuros Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kuros Biosciences AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kuros Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kuros Biosciences AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Kuros Pink Sheet
Kuros Biosciences financial ratios help investors to determine whether Kuros Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kuros with respect to the benefits of owning Kuros Biosciences security.